---
title: 'PSMA-targeted radiotheranostics in modern nuclear medicine: then, now, and
  what of the future?'
date: '2024-06-10'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38855174/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240610182540&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: In 1853, the perception of prostate cancer (PCa) as a rare ailment prevailed,
  was described by the eminent Londoner surgeon John Adams. Rapidly forward to 2018,
  the landscape dramatically altered. Currently, men face a one-in-nine lifetime risk
  of PCa, accentuated by improved diagnostic methods and an ageing population. With
  more than three million men in the United States alone grappling with this disease,
  the overall risk of succumbing to stands at one in 39. The intricate clinical ...
disable_comments: true
---
In 1853, the perception of prostate cancer (PCa) as a rare ailment prevailed, was described by the eminent Londoner surgeon John Adams. Rapidly forward to 2018, the landscape dramatically altered. Currently, men face a one-in-nine lifetime risk of PCa, accentuated by improved diagnostic methods and an ageing population. With more than three million men in the United States alone grappling with this disease, the overall risk of succumbing to stands at one in 39. The intricate clinical ...